Summary of Significant Accounting Policies (Details) (USD $)
|
12 Months Ended | 9 Months Ended | |||
---|---|---|---|---|---|
Mar. 31, 2015
|
Mar. 31, 2014
|
Mar. 31, 2013
|
Dec. 31, 2014
|
Sep. 30, 2013
|
|
Inventories | |||||
Increase in inventory charges | $ 1,000,000us-gaap_IncreaseDecreaseInDeferredCharges | ||||
Long-Lived Assets | |||||
Impairment | 0us-gaap_AssetImpairmentCharges | ||||
Revenue | |||||
Term for advance payment from shipment of sales | 90 days | ||||
Research and Development ("R&D") | |||||
Total offsets to R&D expenses | 500,000cpst_ResearchAndDevelopmentOffsetToExpenses | 1,400,000cpst_ResearchAndDevelopmentOffsetToExpenses | 1,700,000cpst_ResearchAndDevelopmentOffsetToExpenses | ||
Risk Concentrations | |||||
Aggregate balances that exceed insurance coverage | 32,000,000us-gaap_CashUninsuredAmount | ||||
Bad debt expense | 10,138,000us-gaap_ProvisionForDoubtfulAccounts | 242,000us-gaap_ProvisionForDoubtfulAccounts | 276,000us-gaap_ProvisionForDoubtfulAccounts | ||
Net Loss Per Common Share | |||||
Options outstanding (in shares) | 13,200,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber | 12,900,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber | 11,800,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber | ||
Outstanding restricted stock units (in shares) | 1,900,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber | 2,100,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber | 1,500,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber | ||
Number of warrants excluded from diluted net loss per common share computations | 0us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount | 0us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount | 26,500,000us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount | ||
Revenue | Customer concentrations | E-Finity | |||||
Risk Concentrations | |||||
Concentration percentage |
19.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_SalesRevenueGoodsNetMember / us-gaap_ConcentrationRiskByTypeAxis = us-gaap_CustomerConcentrationRiskMember / us-gaap_MajorCustomersAxis = cpst_EFinityDistributedGenerationMember |
||||
Revenue | Customer concentrations | Horizon | |||||
Risk Concentrations | |||||
Concentration percentage |
17.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_SalesRevenueGoodsNetMember / us-gaap_ConcentrationRiskByTypeAxis = us-gaap_CustomerConcentrationRiskMember / us-gaap_MajorCustomersAxis = cpst_HorizonPowerSystemsMember |
12.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_SalesRevenueGoodsNetMember / us-gaap_ConcentrationRiskByTypeAxis = us-gaap_CustomerConcentrationRiskMember / us-gaap_MajorCustomersAxis = cpst_HorizonPowerSystemsMember |
27.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_SalesRevenueGoodsNetMember / us-gaap_ConcentrationRiskByTypeAxis = us-gaap_CustomerConcentrationRiskMember / us-gaap_MajorCustomersAxis = cpst_HorizonPowerSystemsMember |
||
Revenue | Customer concentrations | BPC | |||||
Risk Concentrations | |||||
Concentration percentage |
11.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_SalesRevenueGoodsNetMember / us-gaap_ConcentrationRiskByTypeAxis = us-gaap_CustomerConcentrationRiskMember / us-gaap_MajorCustomersAxis = cpst_BankingProductionCentreMember |
17.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_SalesRevenueGoodsNetMember / us-gaap_ConcentrationRiskByTypeAxis = us-gaap_CustomerConcentrationRiskMember / us-gaap_MajorCustomersAxis = cpst_BankingProductionCentreMember |
11.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_SalesRevenueGoodsNetMember / us-gaap_ConcentrationRiskByTypeAxis = us-gaap_CustomerConcentrationRiskMember / us-gaap_MajorCustomersAxis = cpst_BankingProductionCentreMember |
||
Accounts receivable allowance |
7,100,000us-gaap_AllowanceForDoubtfulAccountsReceivable / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_SalesRevenueGoodsNetMember / us-gaap_ConcentrationRiskByTypeAxis = us-gaap_CustomerConcentrationRiskMember / us-gaap_MajorCustomersAxis = cpst_BankingProductionCentreMember |
||||
Net accounts receivable | Credit concentration | E-Finity | |||||
Risk Concentrations | |||||
Concentration percentage |
16.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_AccountsReceivableMember / us-gaap_ConcentrationRiskByTypeAxis = us-gaap_CreditConcentrationRiskMember / us-gaap_MajorCustomersAxis = cpst_EFinityDistributedGenerationMember |
||||
Net accounts receivable | Credit concentration | BPC | |||||
Risk Concentrations | |||||
Concentration percentage |
26.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_AccountsReceivableMember / us-gaap_ConcentrationRiskByTypeAxis = us-gaap_CreditConcentrationRiskMember / us-gaap_MajorCustomersAxis = cpst_BankingProductionCentreMember |
17.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_AccountsReceivableMember / us-gaap_ConcentrationRiskByTypeAxis = us-gaap_CreditConcentrationRiskMember / us-gaap_MajorCustomersAxis = cpst_BankingProductionCentreMember |
|||
Accounts receivable allowance |
$ 2,600,000us-gaap_AllowanceForDoubtfulAccountsReceivable / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_AccountsReceivableMember / us-gaap_ConcentrationRiskByTypeAxis = us-gaap_CreditConcentrationRiskMember / us-gaap_MajorCustomersAxis = cpst_BankingProductionCentreMember |
||||
Net accounts receivable | Credit concentration | EMI | |||||
Risk Concentrations | |||||
Concentration percentage |
18.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_AccountsReceivableMember / us-gaap_ConcentrationRiskByTypeAxis = us-gaap_CreditConcentrationRiskMember / us-gaap_MajorCustomersAxis = cpst_ElectroMecaniqueIndustriesMember |
||||
Minimum | |||||
Depreciation and Amortization | |||||
Estimated Useful Life | 2 years | ||||
Maximum | |||||
Depreciation and Amortization | |||||
Estimated Useful Life | 10 years | ||||
Warranty | |||||
Warranty period | 18 months |
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
Represents the period of warranty service provided by the entity on its products and services. No definition available.
|
X | ||||||||||
- Definition
Represents the amount of grant distributions and development funding that has been offset to research and development expenses. No definition available.
|
X | ||||||||||
- Definition
Represents the term of advance payment from shipment of sales. No definition available.
|
X | ||||||||||
- Definition
For an unclassified balance sheet, a valuation allowance for receivables due a company that are expected to be uncollectible. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Definition
Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Definition
The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation. No definition available.
|
X | ||||||||||
- Definition
For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. No definition available.
|
X | ||||||||||
- Definition
Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Definition
Number of options outstanding, including both vested and non-vested options. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|